GMP IPO Watch
1. Live IPO Status & Subscription Details
The IPO window is now active. Unlike many SME issues that use a fixed price, KRM Ayurveda is a Book Built Issue, allowing investors to bid within a specific price range.
Subscription Period: January 21, 2026 – January 23, 2026.
Price Band: ₹128 to ₹135 per share.
Lot Size: 1,000 shares (Retail requires a minimum of 2 lots / 2,000 shares, totaling ₹2,70,000).
Anchor Round: The company successfully raised ₹20.82 crore on January 20 from institutional investors, signaling strong professional interest before the public launch.
2. Updated IPO Timeline (Key Dates)
| Event | Date |
|---|---|
| IPO Closes | Friday, January 23, 2026 (5:00 PM) |
| Allotment Basis | Tuesday, January 27, 2026 |
| Refunds/Credit of Shares | Wednesday, January 28, 2026 |
| Listing Date | Thursday, January 29, 2026 |
| Listing Platform | NSE SME (NSE Emerge) |
3. Grey Market Premium (GMP) & Valuation
As of today, the unofficial GMP stands at approximately ₹21, which is roughly 16% above the issue price.
Estimated Listing Price: ~₹156 per share.
P/E Ratio: At the upper price band of ₹135, the post-issue P/E ratio is roughly 23.73x.
Peer Comparison: This is significantly more attractive than its listed peers like Jeena Sikho Lifecare (P/E ~76x) and Vaidya Sane (P/E ~93x), suggesting a potential "valuation gap" that could benefit early investors.
4. Deep Dive: The Telemedicine Pivot
A significant portion of the ₹77.49 crore proceeds (₹13.67 Cr) is earmarked for a unified Telemedicine Operational Facility.
Global Outreach: The company is moving away from being purely a "hospital chain" to a "digital healthcare provider."
The "AyuKarma" Brand: Proceeds will also fund the expansion of their D2C (Direct-to-Consumer) brand, which currently sells over 300 Ayurvedic products globally.
5. Essential Risk Factors to Monitor
Geographical Bias: Over 60% of revenue still comes from Delhi and Haryana. Success depends on the telemedicine platform's ability to diversify this.
Staff Turnover: Historically, the company had high attrition (78% in FY24), though it improved to 31% in FY25. Consistency in medical staff is vital for patient trust.
Insurance Cycles: About 15–20% of their revenue is tied to insurance providers with 150-180 day payment cycles, which can strain cash flow.
6. Final Verdict: Subscribe or Avoid?
Subscribe for Listing Gains: With a 16% GMP and reasonable valuation compared to peers, there is a strong case for short-term gains.
Hold for Long Term: If you believe in the "Atmanirbhar" push for Ayurveda and the scalability of digital health, the company's 15.8% PAT margin and 67% ROE make it a solid long-term contender in the wellness space.
